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Abstract
Subanaesthetic ketamine has recently been proven to be a highly effective and fast acting
alternative treatment for several psychiatric disorders. The mechanisms responsible for
ketamine’s antidepressant effects remain unclear, but a possible explanation could be that
ketamine interacts with regional cerebral blood flow (rCBF). Therefore, the effects of two
subanaesthetic ketamine doses on rCBF were evaluated. Twelve dogs were randomly
assigned to one of the three treatment conditions (condition saline, condition 0.5 mg/kg
ketamine or condition 2 mg/kg ketamine) and received in total five saline or ketamine infu-
sions, with one week interval. Single Photon Emission Computed Tomography (SPECT)
scans with the radiotracer 99mTc-hexamethylpropylene amine oxime were performed before
the start of the infusions (baseline) and 24 hours after the first (single) and last (multiple)
infusion. After a wash out period of 3 months, the animals were again assigned to one of the
three treatment conditions described above and the infusion/scan protocol was repeated.
During the infusions, cardiovascular parameters were evaluated every ten minutes. A one-
way repeated measure ANOVA was set up to assess perfusion index for each ketamine
dose for the left frontal cortex (alpha = 0.05). The remaining 11 brain regions were post hoc
assessed. Perfusion index was significantly increased in the left frontal cortex and in the
thalamus 24 hours after single and multiple ketamine infusions compared to baseline in the
2 mg/kg condition. No clinically relevant cardiovascular effects were observed during the
ketamine infusions. This study shows that subanaesthetic ketamine can increase neuronal
perfusion and therefore alter neuronal function in brain regions involved in depression and
anxiety disorders. These perfusion increases may possibly contribute to ketamine’s benefi-
cial effects in these psychiatric disorders.
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Introduction
Ketamine, a dissociative anaesthetic, is routinely used in human and veterinary medicine [1].
It mainly acts as a non-competitive N-methyl-D-aspartate receptor antagonist but in combina-
tion with norketamine, its active metabolite, targets other receptors. These include the dopa-
mine D2 receptor and opioid receptors [2] and the 5-HT2A receptor [3,4].
In human medicine, the current clinical value of ketamine, besides its well-known anaes-
thetic properties, lies mainly in psychiatry and pain management [5]. In psychiatry, subanaes-
thetic dosed ketamine has already been shown to be a rapid and effective treatment for bipolar
disorder, suicidal ideation and major depressive disorder (MDD) [6–11]. Ketamine has also
demonstrated efficacy for Post-Traumatic Stress Disorder (PTSD) [12].
A classic ketamine treatment scheme for MDD consists of intravenous administration of
0.5 mg/kg ketamine infused over 40 minutes [6–9]. Importantly, the effects of a single keta-
mine infusion last long after the drug is metabolized (beyond its 3h half-life in humans) with
sustained responses for up to one week on average [6,8,9]. Moreover, repeated ketamine infu-
sions may prolong the durability of the antidepressant response and are associated with higher
response and remission rates compared with a single infusion [13–15].
In veterinary medicine ketamine is routinely used both in small animals and in large ani-
mals, mainly for its sedative, anaesthetic, and analgesic properties. In subanaesthetic doses in
dogs, ketamine is used in combination with other analgesics to augment analgesia in the peri-
and postoperative period [16,17]. Ketamine has been proven to be particularly useful for the
management of neuropathic pain [18]. When used for pain management, low doses of keta-
mine are administered by constant rate infusion, usually as an adjunct to other analgesics such
as morphine or fentanyl [16,17].
Although there has been increasing interest in the use of ketamine in human psychiatry, no
consensus has been reached on the neurobiological mechanisms accounting for ketamine’s
effects on patients with mood and anxiety disorders [3,19]. An animal model may be helpful in
unravelling its mechanism of action. The dog is considered to be a valuable animal model for
several human psychiatric conditions [20,21]. Not only because dogs exhibit naturally occur-
ring behavioural disorders that are homologues to certain human psychiatric conditions [20],
but also since several functional imaging studies demonstrated similar changes in neuronal
activity and cerebral blood flow. These changes were reported both in dogs [22–25] and in
humans suffering from behavioural disorders such as anxiety disorders, impulsive aggression,
and compulsive disorders [26–28]. The left frontal cortex is strongly implicated in the patho-
physiology of these behavioural disorders, both in humans and dogs, and altered perfusion of
this brain region is a common characteristic in these diseases [26,27,29–31]. Additionally, vari-
ous studies in human and veterinary medicine showed altered perfusion in the (left) frontal
cortex, following administration of subanaesthetic ketamine [32–37]. All these studies focused
on regional cerebral blood flow (rCBF) evaluation during or shortly after a single ketamine
infusion. Since responses after a single ketamine infusion can last up to one week or longer, it
would be interesting to evaluate rCBF at a later stage (24h) following the termination of the
infusion and after multiple ketamine infusions. As such, more insights in the neurobiological
effects and optimization of the ketamine dosing protocol could lead to a more successful ther-
apy for patients with MDD and/or anxiety disorders.
Therefore, the first objective of the current study was to evaluate the effects of two suba-
naesthetic ketamine doses on left frontal cortical perfusion in healthy dogs, 24 hours after sin-
gle and multiple ketamine infusions, placebo controlled, measured with Single Photon
Emission Computed Tomography (SPECT). A second objective was to identify possible
adverse effects of the two ketamine doses on cardiovascular parameters and on behaviour.
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Materials and methods
Animals
Twelve neutered adult dogs (10 females, 2 males; Beagles; age 2.7 ± 0.3 years; weight 11.7 ± 0.8
kg) were included in this study. The animals had no history of neurological or behavioural dis-
orders and were classified as healthy based on general clinical examination. This study was
approved by the local Ethical Committee of the Faculty of Veterinary Medicine, Ghent Univer-
sity (EC 2015_130 and EC 2016_60) and all procedures were performed according to good ani-
mal practice. Welfare of the animals was respected at each time and great care was taken to
avoid stress and anxiety. No animals were sacrificed. The dogs were provided by the small ani-
mal department and the department of veterinary medical imaging and small animal orthope-
dics of the faculty of veterinary medicine. The dogs were socially-housed in small groups (2 to 8
dogs) on an internal surface of 15 m2 with permanent access to an outside area of 15 m2. The
bedding material in the inner part consisted of wood shavings. Feeding toys, such as Kongs
were provided on a regular basis. Twice a day, the animals were allowed to run and play outside
in an enclosed play area, enriched with climbing platforms, hiding places and small bushes. In
addition, the dogs were regularly walked by students of the faculty of veterinary medicine.
Study design
The effects of two subanaesthetic ketamine doses (0.5 mg/kg and 2 mg/kg, Nimatek, Eurovet
Animal Health B.V, Bladel, Nederland) on rCBF were examined, using Single Photon Emis-
sion Computed Tomography (SPECT) with the radiotracer 99mTc-hexamethylpropylene
amine oxime. A sample size calculation was performed based on a prediction linear mixed
model with a delta (predicated difference) equal to 0.05 and a power of 0.80. This provided a
sample size of 7.48 animals per group. Consequently, a sample size of 8 animals per group was
chosen. Therefore, in the first part of the study, twelve dogs were randomly divided into three
groups, with one group receiving ketamine at a dose of 0.5 mg/kg (condition 0.5 mg/kg), one
group receiving ketamine at 2 mg/kg (condition 2 mg/kg) and one group receiving saline (con-
dition saline). Each animal received in total five ketamine or saline infusions, with one week
interval. SPECT scans were performed at three time points: one to two weeks prior to the infu-
sions (baseline scan) and 24 hours after the first (single) and last (fifth/multiple) infusion (Fig
1). In all groups, the total dose of ketamine or saline was administered intravenously over
40-minutes. The dosages used are in the order of what it is described in human psychiatry,
taken into account differences in pharmacokinetics between species [6–9]. Prior to the infu-
sions, the dogs were sedated intramuscularly in order to avoid side effects due to the ketamine
administration. A wash out period of 3 months was respected before the second part of the
study was initiated. In this second part of the study, the animals were reused and again
assigned to one of the three treatment conditions described above. Once again, each dog
received five weekly ketamine or saline infusions, preceded by a baseline SPECT scan and fol-
lowed by a SPECT scan after the first and fifth infusion. In summary, each animal underwent
the infusion/scan protocol twice, although different treatment, with a wash-out period of three
months in between the two sessions. Consequently, all dogs participated in two of the three
treatment conditions and eight dogs were included in each treatment condition.
A validated questionnaire (Canine Behavioural Assessment and Research Questionnaire,
C-BARQ) was used to score each dog’s behaviour before and after the ketamine or saline adminis-
trations [38]. As not all categories of the questionnaire were relevant for this study, only items
regarding aggression, fear and anxiety were evaluated. The principal animal caretaker completed
the questionnaires. Responses were evaluated in terms of intensity of the behaviours (aggression,
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fear and anxiety), using a 5-point qualitative rating scale (0 = no signs of the behaviour, 1 to
3 = mild to moderate signs of the behaviour, and 4 = severe signs of the behaviour).
Ketamine administration protocol
Following intramuscular sedation with dexmedetomidine (375 μg/m2 body surface, Dexdomi-
tor, Orion Corporation, Espoo, Finland), an intravenous 22G over-the-needle catheter
(Optiva, Jelco Smiths Medical International Ltd, Rossendale, UK) was placed in one of the
cephalic veins. The animals were then allowed to relax in a quiet room until an appropriate
level of sedation was obtained. The sedation scoring system, described by Carter et al. [39] was
used. The level of sedation was assessed on a numeric rating scale where 0 = no sedation;
1 = standing or sitting and head lower than before sedation; 2 = standing or sitting unbalanced,
muscle weakness and refusing to lie down; 3 = lying in sternal recumbency but responsive;
4 = lying in lateral recumbence but responsive; and 5 = lying in lateral recumbency and unre-
sponsive. When a sedation score of 4 or 5 was reached, usually after 20 to 30 minutes, the
infusions were started. A constant rate infusion (CRI) of ketamine or saline was given intrave-
nously at a rate of 0.0125 ml/kg/min, over a 40-minute time period using a syringe driver (B.
Braun Melsungen AG, Perfusor space, Melsungen, Germany). During the infusions, the prin-
cipal investigator monitored the animals and cardiovascular parameters and sedation scores
were evaluated every ten minutes. Following termination of the infusion, the cephalic catheter
was removed and the animals were allowed to recover.
Anaesthetic protocol
SPECT acquisitions were obtained under general anaesthesia. All dogs were premedicated
intramuscular with 375 μg/m2 body surface dexmedetomidine approximately 30 minutes prior
Fig 1. Schematic overview of the study design. Each animal underwent the infusion/scan protocol twice, although different treatment, with a wash out period of three
months in between the two sessions.
https://doi.org/10.1371/journal.pone.0209316.g001
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to induction in a quiet dimmed room. Next, a 22G over-the-needle cephalic catheter was
placed in one of the front legs to gain intravenous access. General anaesthesia was induced
with propofol (Propovet Multidose, Abbott Laboratories, Berkshire, United Kingdom) given
intravenously to effect and maintained with isoflurane (Isoflo, Abbott Laboratories, Berkshire,
UK) in oxygen using a rebreathing system. During the general anaesthesia, heart rate, respira-
tory rate, end tidal carbon dioxide concentration and arterial haemoglobin oxygen saturation
were measured by means of a calibrated multigas analyzer (Capnomac Ultima, Datex, Hel-
sinki, Finland) and a pulse oximeter (N5500 Patient Monitor, Nellcor Puritan Bennett Inc.,
Pleasanton, CA, U.S.A.).
SPECT perfusion imaging
Regional cerebral blood flow was evaluated with SPECT using the 99mTc-labelled tracer
HMPAO (d, 1, hexamethylpropylene amine oxime, Ceretec, GE healthcare LTD, UK). This is
a validated technique to study rCBF in dogs [40,41]. The lipophilic tracer passes the blood
brain barrier and is taken up by neurons, in a manner proportionally to cerebral blood flow
and neuronal function. In the neurons, it is transformed into a hydrophilic form and becomes
trapped intracellular [40]. After dexmedetomidine premedication, a cephalic catheter was
placed and the tracer was administered intravenously (30.9 MBq/kg ± 3.0 MBq). All SPECT
acquisitions were started between 10 to 20 minutes after tracer injection. Prior to the acquisi-
tion, all dogs were placed in ventral recumbence. The triple headed gamma camera (Triad,
Trionix, Twinsburg, OH, USA) was equipped with low-energy ultrahigh resolution parallel
hole collimators (tomographic resolution full width at half maximum = 9 mm). To facilitate
comparison between dogs, camera and table positioning were standardized. Data were
acquired over a circular 360-degree rotation, for 20 minutes in step-and-shoot mode (120
steps, 10 seconds per step, 3 degree per step) on a 128 x 128 matrix. Images were then pro-
cessed using iterative reconstruction and a Butterworth filter (cut-off 1.6 cycli/cm, order 10,
ten iterations, eight subsets). Pixel size was 1.72 mm [24].
Image analysis
The individual patient’s perfusion images were automatically registered to a template, gener-
ated from 14 dogs (9 males, 5 females, mean age 50 months ± 20), using Brain Registration
and Automated SPET Semiquantification software (BRASS, Nuclear diagnostics, Sweden)
[22]. This template based automated registration method eliminates subjective operator
dependent region definition and the automatic registration (allowing shifting, scaling and
rotation of the data) facilitates the fitting procedure to the template, necessary to compensate
for intra-individual differences in anatomical brain size and shape. On this template, a region
map was generated, including 11 separate manually drawn volumes of interest (VOI) posi-
tioned over the frontal, temporal, parietal and occipital lobes of both hemispheres as well as
over the cerebellum and the basal ganglia and thalamus (Fig 2). To calculate the rCBF ratios
(perfusion index (PI)), regional radioactivity was normalized to the radioactivity of the entire
brain.
Statistical analysis
A one-way repeated measure ANOVA was set up for each subanaesthetic ketamine dose for
the left frontal cortex. The significance level was set at 0.05. The assumptions of normality of
the error term, homoscedasticity and independence of the error term were checked by means
of diagnostics plots and statistical tests (Shapiro Wilk, Levene’s Test). After Bonferroni correc-
tion for multiple testing, the remaining 10 brain regions were post hoc assessed with a type I
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error of 0.005. The analysis was performed in SPSS 23 (The Statistical Package for Social Sci-
ence SPSS Inc, USA).
Paired student’s t-statistics were applied to compare pre and post ketamine C-BARQ scores.
The significance level was again set at 0.05.
For the evaluation of the heart rate, statistical analysis was computed using Rstudio 1.0.136
(R: A Language and Environment for Statistical Computing; R Core Team; R Foundation for
Statistical Computing, Vienna, Austria, 2016, https://www.R-project.org/) with packages
MASS (version 7.3–45), doBy (version 4.6–1), lme4 (version 3.1–137) and LmerTest (version
3.0–1).
Onto the data set a nested linear mixed model with heterogeneous (unstructured) variances
was set up. The model was written as E(Yt|T1,T2) = β0 + β1t1 + β2t2 + β3t3 + β4t4 + β5T1 +
β6T2+ β7t1T1 + β8t2T1 + β9t3T1 + β10t4T1 + β11t1T2 + β12t2T2 + β13t3T2 + β14t4T2 with
Yt as response variable. Heart rate was set as response value whereas time infusion and treat-
ment (both categorical) were set as predictor value. The factors infusion and animal (categori-
cal) were set as random factors. The predictor time infusion (t) denotes the different time
points with t1 the first of five (k-1 = 5–1 = 4) dummies (= 1 if time point = “10 minutes” or 0
otherwise), t2 the second dummy (= 1 if time point = “20 minutes” or 0 otherwise), t3 (= 1 if
time point = “30 minutes” or 0 otherwise) and t4 (= 1 if time point = “40 minutes” or 0 other-
wise). The treatment predictor (T) indicated the different treatment modalities with T1 the
Fig 2. Dorsal (HX), transversal (TX) and sagittal (SX) images of the brain of a dog, obtained with 99mTc-HMPAO
SPECT. The left frontal cortex is indicated by the red cross.
https://doi.org/10.1371/journal.pone.0209316.g002
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first of two (k-1 = 3–1 = 2) dummies (= 1 if treatment = “0.5 mg/kg” or 0 otherwise) and T2 (=
1 if treatment = “2 mg/kg” or 0 otherwise). The reference level (for each region) was set as the
heart rate at baseline in condition saline (intercept). The type-I error was set at 0.05 (two-
tailed). The assumptions of linearity of the regression function and the normality of the error
term were assessed by making diagnostics plots.
Results
Table 1 shows that the average PI of the saline and 0.5 mg/kg condition stays at baseline for the
left frontal cortex. Within the 2 mg/kg condition the average PI of the left frontal cortex dif-
fered significantly over time (p = 0.003). This dose provoked in this region an increase in PI 24
hours after a single infusion (p = 0.001), which remained at that level 24 hours after completion
of the infusion series (p = 0.001) (Fig 3).
The post-hoc analysis revealed only a significant difference within the 2mg/kg condition
for the thalamic region (p = 0.004). At this dose, perfusion index was significantly increased 24
hours after single (p = 0.001) and multiple (p = 0.006) ketamine infusions compared to base-
line (Fig 4).
Concerning the heart rate, the linear mixed model revealed for the 0.5 mg/kg condition a
significant time by treatment interaction for the time points 3 to 5 during the ketamine infu-
sions (S2 Table). These results indicate an increase in heart rate at 20 (p = 0.003), 30
(p = 0.003) and 40 minutes (p = 0.015) after the start of the infusion, compared to the reference
level. For the 2mg/kg condition, all time by treatment interaction terms were significant (with
p< 0.001), indicating a significant increase in heart rate at 10, 20, 30, and 40 minutes after the
start of the infusion (S2 Table). However, at all time points during the ketamine infusions,
heart rate remained within physiological limits [42] and no clinically relevant adverse effects
were observed.
In all three treatment conditions, the C-BARQ questionnaire revealed no significant differ-
ences in behaviour scores after ketamine infusions relative to baseline values.
Discussion
In this healthy dog study, a single subanaesthetic dose of ketamine (2mg/kg) caused an
increase in regional cerebral perfusion in the left frontal cortex and in the thalamic region. In
the 0.5 mg/kg condition, as well as in condition saline, no significant changes in cerebral perfu-
sion were observed. The perfusion alterations in the 2 mg/kg condition were still present 24
hours after ketamine infusion. Similar increases in left frontal blood flow were demonstrated
Table 1. Descriptive statistics for the perfusion index of the left frontal cortex and thalamus, measured at baseline and 24 hours after single and multiple ketamine
(0.5 or 2 mg/kg) or saline infusions (n = 24).
Baseline Single infusion Multiple infusions
Mean SD Min Max Mean SD Min Max Mean SD Min Max
Left frontal
saline 1.12 0.04 1.05 1.18 1.13 0.03 1.08 1.17 1.14 0.02 1.11 1.16
0.5 mg/kg 1.12 0.02 1.07 1.14 1.13 0.03 1.08 1.19 1.12 0.02 1.08 1.15
2 mg/kg 1.11 0.02 1.08 1.15 1.15 0.03 1.10 1.20 1.15 0.02 1.13 1.18
Thalamus
saline 1.17 0.07 1.02 1.25 1.17 0.05 1.10 1.25 1.17 0.03 1.12 1.22
0.5 mg/kg 1.18 0.05 1.10 1.27 1.19 0.06 1.10 1.27 1.18 0.06 1.10 1.25
2 mg/kg 1.15 0.05 1.06 1.24 1.18 0.04 1.12 1.25 1.19 0.05 1.15 1.31
https://doi.org/10.1371/journal.pone.0209316.t001
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in another SPECT study after acute subanaesthetic ketamine infusion in dogs [35]. Also in
humans, several studies investigating the effect of subanaesthetic doses of ketamine have dem-
onstrated increases in rCBF in frontal and thalamic regions [33,34,37]. These similar results in
both species support the assumption to use the dog as a valuable animal model to investigate
the neurobiological effects of low-dose ketamine infusions in humans. However, all of the
studies mentioned above, both in dogs and humans, evaluated rCBF during or shortly after a
single ketamine infusion. In contrast, our study showed that the regional changes in cerebral
blood flow were still detectable 24 hours after ketamine administration corresponding with
peak antidepressant responses observed in human patients [43]. These prolonged perfusion
alterations, beyond ketamine’s biological half-life, are in line with ketamine’s sustained antide-
pressant actions in human psychiatric diseases and could be one of the mechanisms through
which ketamine exerts its effects. Nevertheless, regional brain perfusion 24 hours after a single
ketamine infusion did not differ from rCBF measured 24 hours after multiple infusions. This
is in contrast with human literature on major depression, where it is described that repeated
ketamine infusions are associated with higher response and remission percentages than single
infusions [13–15]. However, in our study, only short term effects of single and repeated
Fig 3. Boxplot of the left frontal cortex perfusion index after single and multiple ketamine infusions relative to baseline for the 2 mg/kg condition. (�< 0.01; ��<
0.001).
https://doi.org/10.1371/journal.pone.0209316.g003
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ketamine infusions were examined and therefore prolonged perfusion alterations following
repeated ketamine administration cannot be excluded.
Significant perfusion changes were only detected in the 2 mg/kg condition. In human psy-
chiatry, ketamine is generally used at a dose of 0.5 mg/kg, with evident clinical responses [6–
9]. In addition, several perfusion studies showed that these low doses were able to increase
rCBF in frontal and thalamic regions [33,34,37]. In our study, a higher dose was needed to pro-
voke significant changes in cerebral perfusion in dogs. A possible explanation could be the dif-
ference in half-life of ketamine between both species. In dogs, the elimination half-life of
intravenous ketamine is approximately 1 hour [18], whereas a half-life of approximately 3
hours is reported in humans [6,44]. Moreover, a higher dose is needed to induce anesthesia in
dogs in comparison with humans [18,45].
The changes in brain perfusion observed after administration of subanaesthetic ketamine
are in line with alterations in cerebral perfusion caused by several other antidepressant treat-
ment options in humans. Decreased perfusion and hypoactivity of the frontal cortex and sub-
cortical limbic structures (including the thalamus) are common characteristics in patients with
MDD and anxiety disorders [26,27,29–31]. Furthermore, response to antidepressant therapy is
Fig 4. Boxplot of the perfusion index of the thalamus after single and multiple ketamine infusions relative to baseline for the 2 mg/kg condition. (�< 0.01; ��<
0.001).
https://doi.org/10.1371/journal.pone.0209316.g004
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generally associated with normalization of rCBF abnormalities in these brain regions.
Increased perfusion in frontal and subcortical brain regions has been demonstrated in patients
responding to treatment with selective serotonin reuptake inhibitors and tricyclic antidepres-
sants [46–48]. Similar changes in brain perfusion were identified in patients successfully
treated with high frequency repetitive transcranial magnetic stimulation over the left frontal
cortex [49,50]. Less consistency is found regarding the changes in rCBF caused by electrocon-
vulsive therapy (ECT) [46,51–53].
We observed profound lateral asymmetry in frontal cortical perfusion after subanaesthetic
ketamine administration, with significant increases in perfusion solely noted in the left hemi-
sphere. This is noteworthy given the fact that reductions in rCBF of the frontal cortex in MDD
patients are predominantly observed on the left [54,55]. In line with rCBF abnormalities found
in humans suffering from MDD and anxiety disorders, also in dogs with pathological anxiety
lower left frontal and subcortical blood flow has been reported [24]. This is an interesting find-
ing, as it means that ketamine could be a valuable adjunctive treatment for dogs with an
incomplete response to standard behavioural therapy and pharmacotherapy, or for dogs with
the need of a faster response. Indeed, additional treatment options for anxiety-disordered dogs
are needed, since the management of behavioural disorders is challenging and treatment out-
come is often unsatisfactory [56–59]. The observations made in the current study strengthen
the hypothesis that ketamine’s influence on rCBF could be an explanation for its antidepres-
sant effects and support the possible use of ketamine as an adjunctive treatment for anxiety in
dogs.
Some authors suggest that the presence or the intensity of dissociative or psychotomimetic
effects during ketamine infusion predicts a more robust and sustained antidepressant response
[60–62]. Even more, the question has raised whether these effects are necessary for rapid anti-
depressant effects to occur. In this study, no adverse behavioural effects were observed during
the ketamine infusions, due to the fact that the dogs were sedated with dexmedetomidine. Fur-
thermore, using the C-BARQ questionnaire, no behavioural changes could be identified fol-
lowing the ketamine infusions. However, since this study included normal dogs, it remains to
be explored whether dexmedetomidine blocks the psychotomimetic effects in behavioural dis-
ordered animals to the same extent.
Using the dexmedetomidine sedative protocol, no clinically relevant cardiovascular effects
were observed during the ketamine infusions.
An important limitation of this study is the fact that the dogs were sedated with dexmedeto-
midine during the ketamine infusions. However, it seems unlikely that this would have influ-
enced scan results, as all scans were performed 24 hours later and dexmedetomidine has a
short half-life of approximately one hour [63]. Dexmedetomidine was administered to avoid
side effects due to the ketamine administration. In human medicine, it was shown that dexme-
detomidine reduced delirium, excitement, and hallucinations caused by ketamine and pro-
duced more haemodynamic stable patients [64]. Also in veterinary medicine,
dexmedetomidine–ketamine is a frequently used combination which provides heavy sedation
or general anaesthesia with less behavioural side effects than ketamine alone [65]. Potential
adverse effects in dogs include sympathomimetic symptoms such as tachycardia and hyperten-
sion, excitement, increased muscle tone and hypersalivation [18]. In the current study, no
behavioural or cardiovascular adverse effects were observed. Another limitation lies in the fact
that the dogs were under general anaesthesia during the brain imaging. As a result, the seda-
tives and anaesthetics used could have influenced imaging results. However, the created
images during scanning process are a reflection of the situation at the moment of tracer injec-
tion, as the tracer becomes trapped intracellular within minutes after injection. Consequently,
all anaesthetics administered later on will have no influence on scan results. Still, sedation with
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dexmedetomidine was performed before tracer injection. However, the influence of this seda-
tive on brain perfusion is established and was taken into account when interpreting results
[36,66]. Important to notice is the fact that an intra-subject comparison was carried out, evalu-
ating the same animal before and after ketamine administration with an identical anaesthetic
protocol thereby eliminating potential sedation effects. In addition, the study design included
a placebo group (condition saline) in order to further exclude sedation effects. A final limita-
tion is that the clinical importance of the observed cerebral perfusion alterations could not be
assessed in this study.
Conclusions
In conclusion, this study demonstrates a dose-related increased regional cerebral blood flow in
the left frontal cortex and thalamus 24 hours after single and multiple subanaesthetic ketamine
administration in healthy dogs. These observations are especially interesting because the brain
regions involved are important in canine and human mood disorders. Therefore, in a further
study, it would be interesting to examine ketamine’s clinical effects in a population of anxiety-
disordered dogs. In addition, the difference in long term effects between single and multiple
ketamine infusions should be examined.
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